{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:11:21Z","timestamp":1784740281535,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.msard.2025.106602","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:43:18Z","timestamp":1751427798000},"page":"106602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Treatment strategies of AQP4-IgG positive neuromyelitis optica spectrum disorder and MOG antibody-associated disorder in Switzerland: a nationwide survey"],"prefix":"10.1016","volume":"102","author":[{"given":"Lukas","family":"Steinegger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Kana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Pot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Gobbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Th\u00e9audin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Zecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Herwerth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2025.106602_bib0001","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.msard.2025.106602_bib0002","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1007\/s00415-019-09440-8","article-title":"Unilateral cortical FLAIR-hyperintense lesions in Anti-MOG-associated encephalitis with seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome","volume":"266","author":"Budhram","year":"2019","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106602_bib0003","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ncl.2023.06.009","article-title":"Updates in NMOSD and MOGAD diagnosis and treatment: a tale of two Central nervous system autoimmune inflammatory disorders","volume":"42","author":"Cacciaguerra","year":"2024","journal-title":"Neurol. Clin."},{"issue":"2","key":"10.1016\/j.msard.2025.106602_bib0004","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2025.106602_bib0005","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamaneurol.2022.0489","article-title":"Association of maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"79","author":"Chen","year":"2022","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106602_bib0006","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s00415-025-12937-0","article-title":"A real-world study on the utility of regular rituximab treatment for neuromyelitis optica spectrum disorder","volume":"272","author":"Chen","year":"2025","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106602_bib0007","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann. Neurol."},{"issue":"10206","key":"10.1016\/j.msard.2025.106602_bib0008","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.msard.2025.106602_bib0009","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1212\/WNL.0000000000207443","article-title":"Rituximab de-escalation in patients with Neuromyelitis Optica spectrum disorder","volume":"101","author":"Demuth","year":"2023","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2025.106602_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurad.2024.101235","article-title":"MRI management of NMOSD and MOGAD: proposals from the French expert Group NOMADMUS","volume":"52","author":"Durand-Dubief","year":"2025","journal-title":"J. Neuroradiol."},{"issue":"2","key":"10.1016\/j.msard.2025.106602_bib0011","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the response to Rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106602_bib0012","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/jnnp-2022-330237","article-title":"Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study","volume":"94","author":"Gastaldi","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106602_bib0013","article-title":"Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD","author":"Haussler","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106602_bib0014","series-title":"Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.)","article-title":"Diagnose und therapie der multiplen sklerose, neuromyelitis-optica-spektrum-Erkrankungen und MOG-IgG-assoziierten Erkrankungen, S2k-Leitlinie, 2023","author":"Hemmer","year":"2023"},{"issue":"11","key":"10.1016\/j.msard.2025.106602_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055392","article-title":"Predictors of relapse in MOG antibody associated disease: a cohort study","volume":"11","author":"Huda","year":"2021","journal-title":"BMJ Open"},{"issue":"23","key":"10.1016\/j.msard.2025.106602_bib0016","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.2169\/internalmedicine.9446-22","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease with frequent cerebellitis","volume":"61","author":"Ishikura","year":"2022","journal-title":"Intern. Med."},{"issue":"7","key":"10.1016\/j.msard.2025.106602_bib0017","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","article-title":"Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106602_bib0018","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000947","article-title":"Discontinuation of immunosuppressive therapy in patients with Neuromyelitis Optica spectrum disorder with aquaporin-4 antibodies","volume":"8","author":"Kim","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.msard.2025.106602_bib0019","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106602_bib0020","series-title":"Jupyter Notebooks \u2013 A Publishing Format for Reproducible Computational Workflows","first-page":"87","author":"Kluyver","year":"2016"},{"issue":"1","key":"10.1016\/j.msard.2025.106602_bib0021","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"Kumpfel","year":"2024","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2025.106602_bib0022","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jamaneurol.2024.2811","article-title":"Time to treat first acute attack of myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"81","author":"Kwon","year":"2024","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106602_bib0023","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.msard.2025.106602_bib0024","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1007\/s10072-021-05079-4","article-title":"Intravenous immunoglobulin as the rescue treatment in NMOSD patients","volume":"42","author":"Lin","year":"2021","journal-title":"Neurol. Sci."},{"issue":"9","key":"10.1016\/j.msard.2025.106602_bib0025","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1177\/13524585231184738","article-title":"Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody disease","volume":"29","author":"Lotan","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106602_bib0026","series-title":"Proceedings of the 9th Python in Science Conference","doi-asserted-by":"crossref","first-page":"51","DOI":"10.25080\/Majora-92bf1922-00a","article-title":"Data structures for statistical computing in Python","author":"McKinney","year":"2010"},{"issue":"6","key":"10.1016\/j.msard.2025.106602_bib0027","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in Aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2025.106602_bib0028","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-positive Neuromyelitis Optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106602_bib0029","series-title":"Collaborative data Science","year":"2015"},{"issue":"1","key":"10.1016\/j.msard.2025.106602_bib0030","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001100","article-title":"Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis Optica spectrum disorders","volume":"9","author":"Ringelstein","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"10","key":"10.1016\/j.msard.2025.106602_bib0031","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.neurol.2024.09.001","article-title":"Eculizumab as rescue therapy in a context of dramatic NMOSD attack: report of two cases","volume":"180","author":"San-Galli","year":"2024","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.msard.2025.106602_bib0032","article-title":"Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks","author":"Schwake","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"10.1016\/j.msard.2025.106602_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2025.106602_bib0034","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/jnnp-2023-331350","article-title":"Acute haemorrhagic leucoencephalitis as clinical manifestation of MOG antibody-associated disease","volume":"94","author":"Skarsta","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"18","key":"10.1016\/j.msard.2025.106602_bib0035","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1212\/WNL.0000000000201263","article-title":"Frequency of new or enlarging lesions on MRI outside of clinical attacks in patients with MOG-antibody-associated disease","volume":"99","author":"Syc-Mazurek","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106602_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102750","article-title":"Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy","volume":"49","author":"Takai","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2025.106602_bib0037","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.msard.2025.106602_bib0038","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1136\/jnnp-2024-333463","article-title":"Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse","volume":"95","author":"Trewin","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"10.1016\/j.msard.2025.106602_bib0039","article-title":"Remedial effect of intravenous cyclophosphamide in corticosteroid-refractory patients in the acute phase of Neuromyelitis Optica spectrum disorder-related Optic neuritis","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106602_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients","volume":"44","author":"Whittam","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106602_bib0041","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2025.106602_bib0042","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106602_bib0043","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3389\/fneur.2020.00642","article-title":"Retrospective observation of low-dose rituximab treatment in Chinese patients with neuromyelitis optica spectrum disorders in a real-world setting","volume":"11","author":"Xiao","year":"2020","journal-title":"Front. Neurol."},{"issue":"22","key":"10.1016\/j.msard.2025.106602_bib0044","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106602_bib0045","article-title":"Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Immunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500344X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500344X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:23:15Z","timestamp":1780039395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482500344X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":45,"alternative-id":["S221103482500344X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106602","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment strategies of AQP4-IgG positive neuromyelitis optica spectrum disorder and MOG antibody-associated disorder in Switzerland: a nationwide survey","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106602","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106602"}}